<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01347736</url>
  </required_header>
  <id_info>
    <org_study_id>MC10CE</org_study_id>
    <secondary_id>NCI-2011-00338</secondary_id>
    <secondary_id>MC10CE</secondary_id>
    <secondary_id>11-00531</secondary_id>
    <secondary_id>NCI-2011-00338</secondary_id>
    <nct_id>NCT01347736</nct_id>
  </id_info>
  <brief_title>Scrambler Therapy in Treating Chronic Pain in Patients With Rash From Varicella Zoster Virus Infection</brief_title>
  <official_title>Scrambler Therapy for the Treatment of Chronic Zoster Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This pilot clinical trial studies how well scrambler therapy works treating chronic pain in&#xD;
      patients with rash from varicella zoster virus infection. Scrambler therapy may help relieve&#xD;
      pain from a rash caused by varicella zoster virus infection&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To explore whether we can decrease post-herpetic neuralgia (PHN) pain with scrambler&#xD;
      therapy.&#xD;
&#xD;
      OUTLINE: Patients undergo scrambler therapy for approximately 30 minutes. Treatment continues&#xD;
      for 10 days in the absence of pain progression or unacceptable toxicity. After the completion&#xD;
      of study treatment, patients are followed up for 10 weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 2011</start_date>
  <completion_date type="Actual">November 7, 2014</completion_date>
  <primary_completion_date type="Actual">November 7, 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in pain on a 0-10 numerical rating scale.</measure>
    <time_frame>10 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Dermatologic Complications</condition>
  <condition>Pain</condition>
  <condition>Viral Infection</condition>
  <arm_group>
    <arm_group_label>Treatment (pain therapy)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergo scrambler therapy for approximately 30 minutes. Treatment continues for 10 days in the absence of pain progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>scrambler therapy</intervention_name>
    <description>Undergo scrambler therapy</description>
    <arm_group_label>Treatment (pain therapy)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>questionnaire administration</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>Treatment (pain therapy)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>dermatologic complications management/prevention</intervention_name>
    <description>Undergo scrambler therapy</description>
    <arm_group_label>Treatment (pain therapy)</arm_group_label>
    <other_name>complications management/prevention, dermatologic</other_name>
    <other_name>management/prevention, dermatologic complications</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Pain of &gt;= 1 month (30 days) duration attributed to zoster, for which the patient&#xD;
             wants intervention&#xD;
&#xD;
          -  Pain at least a four out of ten problem during the prior week, on a 0-10 scale where&#xD;
             zero was no problem and ten was the worst possible problem&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) = 0, 1, or 2&#xD;
&#xD;
          -  Life expectancy &gt;= 3 months (90 days)&#xD;
&#xD;
          -  Ability to complete questionnaire(s) by themselves or with assistance&#xD;
&#xD;
          -  Provide informed written consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any of the following because this study involves an investigational agent whose&#xD;
             genotoxic, mutagenic and teratogenic effects on the developing fetus and newborn are&#xD;
             unknown&#xD;
&#xD;
          -  Pregnant women&#xD;
&#xD;
          -  Patients with implantable drug delivery systems, e.g. Medtronic Synchromed&#xD;
&#xD;
          -  Patients with heart stents or metal implants such as pacemakers, automatic&#xD;
             defibrillators, aneurysm clips, vena cava clips and skull plates; (metal implants for&#xD;
             orthopedic repair, e.g. pins, clips, plates, cages, joint replacements are allowed as&#xD;
             are central venous access devices)&#xD;
&#xD;
          -  Patients with a history of myocardial infarction or ischemic heart disease within the&#xD;
             past six months&#xD;
&#xD;
          -  Patients with history of epilepsy, brain damage, use of anti-convulsants for seizure&#xD;
             prevention, symptomatic brain metastases; Note: anti-convulsant use is allowed for&#xD;
             neuropathy and heart failure (HF) if on a stable dose&#xD;
&#xD;
          -  Other identified causes of pain in the area that was affected by herpes zoster&#xD;
&#xD;
          -  Skin conditions such as open sores that would prevent proper application of the&#xD;
             electrodes&#xD;
&#xD;
          -  Other medical or other condition(s) that in the opinion of the investigators might&#xD;
             compromise the objectives of the study&#xD;
&#xD;
          -  Prior treatment with Calmare MC-5A therapy&#xD;
&#xD;
          -  Patient initiation of a new analgesic treatment within 7 days prior to initiation of&#xD;
             protocol treatment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Charles Loprinzi</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <study_first_submitted>March 30, 2011</study_first_submitted>
  <study_first_submitted_qc>May 3, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 4, 2011</study_first_posted>
  <last_update_submitted>April 2, 2018</last_update_submitted>
  <last_update_submitted_qc>April 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 4, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Virus Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

